Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 2/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | PRMT6 | Q96LA8 | 3/20 | 0.54 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.53 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.53 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.53 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.53 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.51 |
| ▸ | MGLL | Q99685 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3981456 | 0.82 | CCR3 (0.61) | CCR3KCNH2PRMT6CARM1PRMT3 | |
| SCHEMBL133620 | 0.79 | CCR3 (0.61) | CCR3PRMT6CARM1PRMT3PRMT1 | |
| SCHEMBL7698046 | 0.79 | CCR3 (0.71) | CCR3KCNH2PRMT6CARM1PRMT3 | |
| SCHEMBL327856 | 0.78 | CCR3 (0.66) | CCR3KCNH2PRMT6CARM1PRMT3 | |
| SCHEMBL16191226 | 0.77 | GBA1 (0.59) | CCR3KCNH2PRMT6CARM1PRMT3 | |
| SCHEMBL360084 | 0.76 | KCNH2 (0.77) | CCR3KCNH2PRMT6CARM1PRMT3 | |
| SCHEMBL12041264 | 0.76 | KCNH2 (0.81) | CCR3KCNH2PRMT6CARM1PRMT3 | |
| SCHEMBL3323940 | 0.75 | PRMT6 (0.60) | CCR3KCNH2PRMT6CARM1PRMT3 | |
| SCHEMBL674276 | 0.74 | GBA1 (0.71) | CCR3PRMT6CARM1PRMT3PRMT1 | |
| SCHEMBL2027845 | 0.74 | GBA1 (0.71) | CCR3PRMT6CARM1PRMT3PRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2764867-A1 | Agents for preventing and treating disorders Involving modulation of the RYR receptors | The Trustees of Columbia University in the City of New York (US) | 2014-08-13 | — | — | EP | claimed |
| US-8288432-B2 | Tetrahydroindole derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2012-10-16 | — | — | US | disclosed |
| US-20100120749-A1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYO TEX SA (CH) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120749-A1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | CYBB, NQO1, NOX4 | CCR3 4047/4885KCNH2 3092/4885PRMT6 2303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.